

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

**VOLUNTARY ANNOUNCEMENT
PHASE III CLINICAL TRIAL OF PROXALUTAMIDE FOR THE
TREATMENT OF HOSPITALIZED COVID-19 PATIENTS
CONDITIONALLY APPROVED BY ANVISA IN BRAZIL**

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**” or “**Kintor Pharma**”) to update its shareholders and potential investors on the latest business advancement of the Group.

The board of directors (the “**Director(s)**”) of the Company (the “**Board**”) is pleased to announce that the phase III clinical trial of proxalutamide for the treatment of hospitalized COVID-19 patients was conditionally approved by the Brazilian Health Regulatory Authority (“**ANVISA**”) on 22 September 2021.

As part of Kintor Pharma’s plan to conduct pivotal multi-regional clinical trials (the “**US, China and International Phase III Clinical Trial (Inpatients)**” or the “**MRCT**”) of proxalutamide for the treatment of hospitalized COVID-19 patients in more than ten countries and regions, following the abovementioned approval, Brazil has become the fourth country to approve the MRCT after the United States, China and the Philippines. The US, China and International Phase III Clinical Trial (Inpatients) (NCT05009732) is a randomized, double-blind, placebo-controlled phase III MRCT, which is expected to enroll 1,030 patients. The primary endpoint is the time to sustained recovery evaluated by Day 30. For further details, please refer to the announcements of the Company dated 18 May 2021 and 1 September 2021, respectively.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that proxalutamide will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

The Board has noted the unusual fluctuation in the price and the trading volume of the shares of the Company (the “**Shares**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) on 24 September 2021. The Board wishes to clarify that the Board is not aware of any reason that caused the fluctuation in the price and trading movements of the Shares or of any information which must be announced to avoid a false market in the Company’s securities pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”), or of any inside information which needs to be disclosed pursuant to the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). As at the date of this announcement, the Board is not aware of any development or update which may result in material adverse impact on the business prospects of the Company.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the Shares. This announcement is made by the order of the Company. The Board collectively and individually accepts responsibility for the accuracy of this announcement.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
Chairman, Executive Director and Chief Executive Officer

Hong Kong, 26 September 2021

As at the date of this announcement, the executive Director is Dr. Youzhi Tong; the non-executive Directors are Mr. Gang Lu, Mr. Weipeng Gao, Dr. Yan Wang, Mr. Wei Zhang and Ms. Yaling Wu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purposes only*